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Lysophospholipids comprise a group of bioactive molecules with multiple biological functions. The cardinal members of this
signalling molecule group are sphingosylphosphorylcholine (SPC), lysophosphatidic acid (LPA), and sphingosine 1-phosphate
(S1P) which are, at least in part, homologous to each other. Bioactive lipids usually act via G-protein coupled receptors (GPCRs),
but can also function as direct intracellular messengers. Recently, it became evident that bioactive lipids play a role during cellular
diﬀerentiation development. SPC induces mesodermal diﬀerentiation of mouse ES cells and diﬀerentiation of promyelocytic
leukemia cells, by a mechanism being critically dependent on MEK-ERK signalling. LPA stimulates the clonal expansion of
neurospheres from neural stem/progenitor cells and induces c-fos via activation of mitogen- and stress-activated protein kinase
1 (MSK1) in ES cells. S1P acts on hematopoietic progenitor cells as a chemotactic factor and has also been found to be critical
for cardiac and skeletal muscle regeneration. Furthermore, S1P promotes cardiogenesis and similarly activates Erk signalling
in mouse ES cells. Interestingly, S1P may also act to maintain human stem cell pluripotency. Both LPA and S1P positively
regulate the proliferative capacity of murine ES cells. In this paper we will focus on the diﬀerential and developmental impact
of lysophospholipids on cardiovascular development.
1.OriginandSynthesis
1.1. Sphingosylphosphorylcholine: Origin and Synthesis. Ly-
sosphingomyelin or sphingosylphosphorylcholine (SPC) has
been initially identiﬁed in the brain of Niemann Pick
type A patients [1] .S P Ca c t sa sb o t ha ne x t r a c e l l u l a r
and intracellular signalling molecule. Although the origin
of circulating SPC is not well characterized, activation of
platelets during clotting is one likely mechanism since serum
contains higher concentrations of SPC than plasma [2–4].
SPC is synthesized from either sphingomyelin or other so
far unknown molecules by diﬀerent metabolic pathways.
In atopic dermatitis, sphingomyelin deacylase activity is
enhanced generating SPC and resulting in sphingomyelin
depletion. This, in turn, leads to decreased ceramide levels
that may be the cause of barrier dysfunction in patients
suﬀering from atopic dermatitis [5]. In addition, certain
diseases, for example, Niemann-Pick type a that exhibit
pathologic SPC accumulation in diﬀerent organs are char-
acterized by a lack of acid sphingomyelinase activity [1]. One
possible explanation for this eﬀect might be that high levels
of sphingomyelin lead to an enhanced degradation by N-
deacylation [3].
1.2. Sphingosine-1-Phosphate: Origin and Synthesis. Sphin-
gosine-1-phosphate (S1P) consists of the 18-carbon base
sphingosine and a phosphate group at the C1 position.
Sphingosine is phosphorylated to S1P by either sphingosine
kinase 1 or 2. S1P can then be metabolized by the S1P
lyase to phosphoethanolamine and hexadecenal, which are
subsequently metabolized into glycerophosph lipids and2 Stem Cells International
phosphatidylethanolamine, respectively. Conversely, S1P-
phosphohydrolase, an ectoenzyme localized in the plasma
membranes of cells, regenerates sphingosine by dephos-
phorylating S1P [6–9]. On the other hand, sphingosine
can be rephosphorylated to S1P [10]. One major source
of circulating S1P is activated platelets which contain a
highly active sphingosine kinase but no S1P lyase [11].
Besides platelets, red blood cells have been identiﬁed to
contain high amounts of S1P [12–14]. Further S1P sources
are provided by direct cellular uptake [8, 15]. Clair and
coworkers demonstrated thatautotaxinhydrolyzes SPC to
S1P. This exoenzyme potently induces tumor cell motility
and enhances experimental (in vitro) metastasis as well as
angiogenesis [16]. However, the physiological relevance of
the conversion of SPC to S1P by this mechanism is as yet
unclear, since there is no detectable S1P in mice lacking
sphingosine kinase 1 and 2 [17].
1.3. Lysophosphatidic Acid: Origin and Synthesis. Lysophos-
phatic acid (LPA) is a glycerophospholipid with a glycerol
backbone.Variabilityinthesatellitegroupsgeneratesdistinct
subforms of LPA with diﬀerent biological functions [18–21].
LPA can be de novo synthesized either by esteriﬁcation of
glycerol-3-phosphate via glycerol phosphate acyltransferase
(GPAT) or by 4 other metabolic pathways: (i) reduction of
acyl dihydroxy acetone phosphate, (ii) phosphorylation of
monoacylglycerol (MAG) by the monoacylglycerol kinase,
(iii) deacylation of phosphatidic acid (PA) by PLA1 or PLA2,
or (iv) via autotaxin hydrolysis of SPC [22–24]. Degradation
of LPA is mediated through either dephosphorylation to
MAG by lipid phosphohydrolases of the PAP type 2 family
(LPP1–3) or conversion to PA by LPA acyltransferase
(LPAAT) or to glycerol-3-phosphate by lysophospholipase
[9], respectively.
2.BioactiveLipidReceptorsandSignalling
Bioactive lipid receptors belong to the family of G-protein
coupled receptors (GPCRs) and are termed LPAR1–5,
S1PR1–5, OGR1, GPR4, and GPR12, respectively [25–27].
Recently, the LPA receptor family has been extended to the
GPCRs P2Y5, GPR87, and P2Y10 which have been shown to
bindbothS1PandLPA[28–32].Especially,OGR1andGPR4
are believed to have a dual function in both lipid signalling
a n dp r o t o ns e n s i n g[ 33]. All GPCRs are proteins containing
seven transmembrane domains with an extracellular N-
terminus and an intracellular C-terminus [34, 35]. There
are two arginines in the extracellular loops one and three
of the S1P and LPA receptors, forming an ion pair with the
phosphates of LPA and S1P. SPC receptors must have a basic
and acidic residue in order to interact with the ammonium
and the phosphate residues of SPC. An additional acidic
residue may be required to interact with the choline base.
till now, three high-aﬃnity receptors have been identiﬁed:
OGR1, GPR4, and GPR12. Most likely, a ligand-binding
pocket is formed by basic and acidic amino acids in the
second and third extracellular loop similar to the S1P and
LPA receptors [36]. In addition, lipid GPCRs also form
heterodimerswitheachother[37].Forfurtherreviewoflipid
receptorfunctionpleasereferto[25].Downstreamsignalling
of these receptors is linked to all types of G-proteins Gs,G i,
Gq,a n dG 12/13,r e s p e c t i v e l y[ 38]. Distinct G-proteins activate
a variety of signalling cascades, predominantly, the MEK-
ERK signalling cascade [39–41] but also crosstalk with other
pathways that are ascribed with respect to bioactive lipid
signalling [42].
3. Lysophospholipids and Their Impact on
CardiovascularDevelopment
Little is known about bioactive lipids and their functions
in cardiogenesis despite the fact that several lipid receptors
are expressed in the cardiac derivates. Most of the so far
published data regarding this link focus on acute eﬀects
mediated by the lipids. Several studies have addressed
the eﬀect of bioactive lipids on cardiac function at the
signal transduction level, for example, by modulating cAMP
signalling [43] and ion conduction followed by changes in
intracellular ion concentrations in the heart. However, the
eﬀects of ion conduction on the sarcoplasmatic reticulum
and cell membrane diﬀer between bioactive lipids such as
S1P and SPC [44]. A study by Nofer et al. has shown
that lysophospholipids stimulate endothelial nitric oxide
production thereby regulating the vascular tone [45]. Nitric
oxide also plays a crucial role in the mobilization and
function of endothelial progenitor cells, an important bone
marrow-derived cell type responsible for endothelial damage
repair,neovascularization and generation of collaterals [46–
48]. Formation of new blood vessels is crucial for both
embryonicdevelopmentandhomeostasisintheadultorgan-
ism. Regarding the expression pattern of lipid receptors
and further development of receptor knockout models, it
has been revealed that bioactive lipids play an important
role during blood vessel formation [49]. Therefore the
following passage will focus on the eﬀects of SPC, S1P,
and LPA on mesodermal development and diﬀerentiation,
predominantly cardiogenesis and angiogenesis.
3.1. Sphingosylphosphorylcholine
3.1.1. Lipid Receptors in Pluripotent Embryonic Stem Cells
of Mice and Men. With respect to stem cells in particular
pluripotent cells the expression of each particular receptor
type varies in distinct cell lines. Our own data show
expression of all S1P and SPC receptors including OGR1
and GPR4 in R1 ES cells. S1PR1–4 and GPR4 are expressed
at high levels. There were no major diﬀerences in receptor
expression between undiﬀerentiated ES cells, diﬀerent EB
stages, or diﬀerent stages of ES cell outgrowths apart from
a slight decrease in the S1PR5 expression level at EB day
2. However, Rodgers and colleagues did not detect S1PR4
in CGR8 and D3 ES cells [40, 41]. To clarify this issue, we
analysed several sets of published transcriptome sets for the
expression of several bioactive lipid receptors in ES and iPS
cellsderivedfrommiceandmen.AsshowninFigures1and2
virtuallyallbioactivelipidreceptorsareexpressedinbothiPS
andEScellsfrombothspecies.ThereisnorelevantdiﬀerenceStem Cells International 3
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Figure 1:Lysophospholipidreceptorexpressioninmurinepluripo-
tent stem cells. Heatmap of microarray gene expression of a list
of mouse bioactive lipid receptors. Gene expression color key is
shown in log2 scale. Microarray data were downloaded from the
GEO database; accession numbers GSE10806.
between the ES and iPS cells pointing to the identity of
both pluripotent cell types. However, the distinct expression
levels of the particular subtypes diﬀer in pluripotent cells of
either murine or human origin. Summarized, bioactive lipid
receptors are widely expressed throughout pluripotent cells
of mice and men. Nevertheless, the precise function of each
s u b t y p er e m a i n su n c l e a rs of a r .
3.1.2. SPC Induces Cardiac Diﬀerentiation of Murine Embry-
onic Stem Cells. To date, there are very limited data linking
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Figure 2: Lysophospholipid receptor expression in human pluripo-
tent stem cells. Heatmap of microarray gene expression of a list
of human bioactive lipid receptors. Gene expression color key is
shown in log2 scale. Microarray data were downloaded from the
GEO database; accession numbers GSE151716.
SPC to mesodermal or cardiac diﬀerentiation. Besides our
own study using the embryonic stem cell diﬀerentiation
modeltocharacterizetheroleofSPCincardiacdevelopment
[40], there are few further studies showing that SPC diﬀeren-
tiates pluripotent and multipotent stem cells [50, 51]. SPC
similar to S1P stimulates cardiac ES cell diﬀerentiation at
the level of both morphology and gene expression. However,
there was no obvious diﬀerence regarding cardiac subtype
formation since SPC increased cardiogenesis during all IVD
stages [40]. Skeletal muscle cells and cardiac cells arise from
the same germ layer [52]. Consequently whole germ layer
induction by SPC is unlikely since otherwise both myogenic
and cardiac cells would have been increased, suggesting
a deﬁned role in later stages of cardiac development, for4 Stem Cells International
example, on progenitor cells. A possible candidate is the
recently identiﬁed multipotent cardiovascular progenitor
which gives rise to cardiomyocytes, endothelial, and vascular
smooth muscle cells [52]. These cells are deﬁned by the
expression of the vascular endothelial growth factor receptor
2 (VEGFR2/FLK1) which was recently shown to crosstalk
with SPC signalling especially during tube formation [42].
This assumption is supported by the ﬁnding that SPC
supports vessel formation in an EB sprouting assay and
furthermore induces expression of endothelial markers (A.
Kleger, unpublished observations). SPC also displays pro-
liferation inducing properties by inﬂuencing ERK-signalling
[53,54].Also,inEScells,SPCleadstoERK-phosphorylation,
suggesting that the increased number of cardiac cells could
be caused by progenitor cell proliferation (Figure 3). This
is unlikely as the SPC-induced gene expression proﬁles
were both atrial (alpha-myosin heavy chain) and ventricular
(myosinlightchain,MLC-2v).RealtimePCRanalysisofboth
transcripts exhibited similar expression proﬁles supporting
theprogenitorcellhypothesis.Simplyincreasedproliferation
would not increase specialized cardiac cells marked by
increased MLC-2v expression. However, there are data that
both SPC and S1P share a common cardiac phenotype.
Similarly, as discussed in detail below, S1P treatment
of EBs increases cardiac diﬀerentiation [55]. In addition, a
developmental study using the zebra ﬁsh model revealed a
S1P receptor as a relevant candidate during cardiogenesis
(see also S1P and cardiac development). This implicates a
kind of “family aﬀair” with respect to cardiac diﬀerentiation.
3.1.3. SPC Plays an Important Role in Angiogenesis. Further
evidence linking SPC to mesodermal development and
diﬀerentiation is given by the eﬀect of SPC on angiogen-
esis. SPC induces diﬀerentiation of endothelial cells into
capillary-like structures in vitro in addition to migration
and chemotaxis of vascular smooth muscle cells [56, 57].
Supporting evidence for a crucial role of SPC in angiogenesis
arises from studies investigating its receptor GPR4. SPC
induces GPR4-dependent vessel formation in vitro from
HUVEC cells [42]. GPR4 deﬁciency leads to leaky blood
vessels (e.g. spontaneous hemorrhages, dilated, tortuous
subcutaneous blood vessels, and defective vascular smooth
muscle cell coverage) during development and the receptor
functions in blood vessels as a pH sensor [49]. S1P and
SPC activate distinct MAP kinase isoforms and increase
[Ca2+]i viadiﬀerent mechanisms in rat cerebralarteries. This
does not aﬀect the ability of both compounds to activate
CREB, although this occurs via diﬀerent pathways [58]. For
further information please refer to [59] where the involved
signalling cascades are discussed in more detail. Piao and
colleagues used a rat aortic ring assay. SPC signiﬁcantly
stimulated the sprouting of endothelial cells from the aortic
ring and markedly enhanced the chemotactic migration and
capillary-like tube formation. This eﬀect was dependent on
a urokinase-type plasminogen activator (uPA), an important
regulator of angiogenesis [60].
3.1.4. SPC Modulates Diﬀerentiation of Several Stem Cell
Populations. Besides end-diﬀerentiation of already commit-
ted endothelial and vascular smooth muscle cells, SPC also
modulates proliferation and diﬀerentiation of multipotent
adult stem cells. Jeon and colleagues investigated SPC eﬀects
in a series of manuscripts on human adipose-tissue-derived
mesenchymal stem cells (hATSCs). In the ﬁrst study Jeon
et al. showed induction of apoptosis under involvement of
the mitochondrial death pathway by SPC in a concentration-
dependent manner (>10μMS P C ) .T h i se ﬀect was critically
dependent on ERK activity [61]. In lower concentrations
the compound induced proliferation of the same cell type
in a JNK-dependent manner without any involvement of
the ERK pathway [51]. A further study revealed SPC as a
diﬀerentiation-inducing agent for hATSCs to smooth muscle
cells. The authors discovered a new signalling pathway
for SPC through Gi/o-ERK-dependent autocrine secretion
of TGF-beta, which activates a Smad2-SRF/myocardin-
dependent pathway (Figure 3). Despite the fact that hATSCs
do not express any known SPC receptors, in all studies SPC
eﬀects seemed to be receptor dependent. This suggests either
a crosstalk with further signalling cascades (e.g., TGF-beta
or VEGF signalling) or involvement of so far unknown SPC
receptors. Another possible explanation would be an SPC-
stimulated release of other bioactive lipids like S1P or LPA
via, for example, autotoxin [50]. The most recent study of
the group identiﬁed ﬁbronectin (FN) as an agent produced
by hATSC after SPC treatment via the pathway described
above. Since ﬁbronectin is essential for cell recruitment
and adhesion during wound healing and angiogenesis, the
authors concluded that SPC-induced FN expression plays
a pivotal role in wound healing by stimulating adhesion
and recruitment of leukocytes [62]. Furthermore, SPC-
mediated TGF-beta release seems not to be restricted to
hATSCs, as also endothelial cells react with release of the
anti-inﬂammatory cytokine after HDL treatment including
SPC and S1P as active compounds [63]. Therefore diﬀerent
local SPC concentrations in distinct microenvironments and
niches seem to regulate the eﬀect of the bioactive lipid.
In summary there are many studies suggesting that SPC
plays a pivotal role in mesodermal development with respect
to cardiogenesis and angiogenesis. Furthermore the key role
of SPC in angiogenesis is deﬁned by coordinated migration
of both endothelial cells and vascular smooth muscle cells
in response to the changing gradients of this bioactive
lipid messenger. SPC eﬀects on both cardiac and vascular
development could be caused by modulation of a common
progenitor as described in [52].
3.2. Sphingosine-1-Phosphate
3.2.1. Cardiovascular Receptor Expression. Expression studies
of the S1P receptor family suggest the particular importance
of S1P in the cardiovascular system. Lung and heart show
the highest overall expression of S1PR1, S1PR2, and S1PR3
[64, 65]. S1PR2 and S1PR3 receptors expression is generally
lower than that of S1PR1 receptors in the heart, although
distribution within cardiac subregions (e.g., ventricle, sep-
tum and atrium) is similar [66, 67]. Beyond that, S1P
receptors are expressed with a distinct expression pattern in
the diﬀerent aortic cell types. High expression levels of S1PStem Cells International 5
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Figure 3: Schematic illustration of SPC-induced diﬀerentiation in murine multipotent and pluripotent stem cells. Signaling pathways
mediating the respected phenotype are noted next to black arrows.
receptors seem to be a general characteristic of endothelial
cells [67–69]. Most of the work was done to clarify acute
eﬀectsofS1Pandotherbioactivelipidsonthecardiovascular
system, for example, the role of S1P during protection
of heart ischemia has been evaluated in several studies
[70–72]. Besides developmental functions and ion channel
modulation,S1Pinducescardiomyocytehypertrophymainly
via the S1PR1 receptor and subsequently via a G protein
through the ERK pathway and via the Rho pathway [73].
3.2.2. S1P and Cardiac Development In Vivo. A developing
action ﬁeld of bioactive lipids is their role in promoting
cardiomyocyte survival and their contribution to ischemic
preconditioning. There are several lines of evidence suggest-
ing that in vivo levels of bioactive lipids inﬂuence cardiomy-
ocyte survival and regeneration. For example, the stress-
activated enzyme S1P lyase (SPL) which metabolizes S1P has
beenidentiﬁedastherapeutictargetforischemia/reperfusion
injury of the heart [74, 75]. Inhibition of SPL results in
elevated levels of S1P [74]. In aging hearts S1P exhibits
cardioprotective eﬀects during cardiac injury in a pre- and
postconditioning experimental setup [75]. Indeed, local S1P
levels seem to regulate not only acute but also developmental
aspects of S1P. The ﬁrst clue for a link between S1P and
cardiac development/diﬀerentiation was given by a study
from Kupperman et al. in the zebraﬁsh model. The authors6 Stem Cells International
investigated the zebraﬁsh analogon of S1PR2, miles apart
(mil), and found that mil speciﬁcally aﬀects the migration
of heart precursors to the midline resulting in cardia biﬁda.
Cross-transplantationstudiessuggestthatS1Pprovidesclues
for the fusion of the bilateral heart progenitors by generating
an environment permissive for migration [76]. This was
further investigated by Kawahara et al. who found that a
mutant of the sphingolipid transporter 2 (spns2) leads to
a similar cardiac defect as the mil mutant. They also could
show that spns2 is involved in the secretion of S1P and
therebyregulatingmyocardialprecursormigration(Figure 4,
[77] ) .F u r t h e re v i d e n c ei sg i v e nb ym e a n so fap r i m a r y
culture system of embryonic zebraﬁsh cells. The interaction
of cardiac precursors with ﬁbronectin, that is, a major
component of the extracellular matrix, seems to be critical
for precursor migration [78]. Recently, a report using a
mouseexvivoculturesystemunderlinedinalienabilityofS1P
for cardiac development in a mammalian system. Wendler
and Rivkees showed that both increased and decreased S1P
levels alter cardiac development by reduced mesenchyme
formation. While decreased S1P levels induce cell death,
increased S1P levels inhibit cellular migration, both resulting
in a reduced amount of mesenchymal transformed cells.
S1PR2 was found to be the most likely candidate for
mediating these eﬀects [79]. Interestingly, Osborne et al.
detected another player involved in the signalling and
traﬃcking of S1P, namely, two of hearts (toh), a spinster
homologue. They found that the mutations are causative of
a cardiac phenotype comparable to that of S1P dysfunction
[80]. In general, developmental acquisition of tolerance to
environmental stress may be contingent upon acquisition
of protective biochemical mechanisms (e.g., S1P-mediated
cellular survival) or simply due to increased cell numbers
(e.g.,S1P-inducedcellularproliferation)[81].Bothissuesare
eventually targeted by S1P during development [44, 82–84].
Regarding intracellular signalling VEGF could be a possible
target of S1P. VEGF activates the sphingosine kinase and
increasesS1Plevelsinhumanumbilicalveinendothelialcells
[85]. Chang and colleagues showed that a distinct regulation
pattern of VEGF is essential for regular valve formation
and morphogenesis [86]. These data indicate that S1P could
be a possible candidate for indirect mediation of VEGF
signalling by induction of sphingosine kinase. Therefore,
lipid signalling and especially accurate regulation of local
concentration in this particular niche are indispensable for
proper function during mammalian heart development and
cellular diﬀerentiation into cardiac tissue.
3.2.3. S1P Signalling during Vasculogenesis-Importance of
VEGF Crosstalk. VEGF is probably the most important
regulator of angiogenesis in both physiological and patho-
logical vessel formation. There are several studies supporting
a crosstalk of VEGF and bioactive lipid signalling. How-
ever, this process seems to be rather complicated: several
mechanisms, for example, transactivation, upregulation, or
downstream activation, are propagated [44]. Igarashi and
colleagues observed that VEGF induces S1PR1 expression.
This process consequently leads, to enhanced intracellular
signalling responses to S1P and the potentiation of S1P-
mediated vasorelaxation. S1P and VEGF signalling leads to,
for example, eNOS regulation which in turn sensitizes the
vascular endothelium to the eﬀects of lipid mediators by
promoting the induction of S1P1 receptors [87]. Further-
more, sphingosine kinase induction has been reported by
VEGF with subsequently altered Ras signalling [85]. Endo
et al. found that S1P induces membrane ruﬄing of human
umbilical vein endothelial cells via the vascular endothelial
growth factor receptor 2 (VEGFR-2) [88]. Most recently,
another study proposed that VEGF induces S1PR3 induction
which is necessary for downstream AKT3 signalling [89].
In summary, there is a well-documented, but still unclear
crosstalk between two angiogenic signalling pathways, which
is not surprising, given the fact that hypoxia, a consequence
ofinsuﬃcientvesselformation,inducesVEGF.Thisissuecan
be clearly followed in a study of Chae et al. They showed
that S1PR1 knockout mice suﬀer from defect limb formation
due to insuﬃcient vessels formation caused by impaired S1P
signalling via S1PR1 leading to hypoxia and VEGF induction
with secondary insuﬃcient hypervascularisation [90].
3.2.4. S1P Receptors Decide on the Angiogenic Phenotype
In Vivo. S1P seems to function on all levels of vascular
development. Lee and colleagues showed S1P induced tube
formation in umbilical vein endothelial cells by means
of a matrigel assay [91]. In several further studies this
eﬀect has been proven in diﬀerent model systems and with
distinct endothelial cell types. Tube formation was critically
dependent on ERK signalling [44, 92, 93]. Recently, HDL
proteinshavebeenimplicatedinservingasaplatformforthe
delivery of S1P. Using reconstituted high-density lipoprotein
(rHDL), Matsuo and colleagues investigated the same eﬀects
as induced by direct incubation with S1P [94].
The last step of angiogenesis is the recruitment of
mural cells, for example, pericytes in capillaries and vascular
smooth muscle cells of arteries [95]. Distinct functions for
S1P in both smooth muscle cells and mural cells have
been reported: S1P modulates and increases smooth muscle
cell migration and diﬀerentiation by Rho Kinase [96]a n d
by RhoA-mediated activation of serum response factor
and involvement of the SRF cofactor, myocardin-related
transcription factor A (MRTF-A). S1P also moderately stim-
ulatedSMCproliferation,aprocessthatwasdependentupon
ERK and involved activation of another SRF cofactor, Elk-
1[ 97]. S1PR1 null mice exhibited embryonic haemorrhage
leading to intrauterine death around embryonic day 13 and
incomplete limb development. Interestingly, these animals
displayed normal vasculogenesis and angiogenesis but failed
to recruit both vascular smooth muscle cells to arteries and
pericytes to capillaries [98]. In the limbs, lack of S1PR1
results in aberrant chondrocyte condensation and irregular
digit morphogenesis. The authors concluded that defective
vascular development induced by lack of S1PR1 caused
hypoxia. Secondary to hypoxia, HIF1 alpha and VEGF
are induced and lead to hypervascularisation, ultimately
disturbinglimbmorphogenesis[90].Inalaterstudy,Allende
and colleagues using a conditional S1PR1 knockout mouse
model targeting endothelial cells found that S1PR1 null
endothelium is defective in mural cell recruitment [99].Stem Cells International 7
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S1P signalling on endothelial cells and bone marrow-derived
stromal cells in vitro results in diﬀerentiation, proliferation,
migration, and tube formation. Diﬀerent studies revealed
that especially S1PR1 but also S1PR2 and -3 to be crucial for
these eﬀects [94, 100]. Since S1PR1 null animals displayed
normal vasculogenesis and angiogenesis, it is likely that
there is functional redundancy among members of the S1P
receptor. This hypothesis is underlined by the fact that
S1PR2 and -3 null mice reveal no apparent anatomical or
physiological defects [64, 101]. Kono and colleagues faced
this issue and created subsequently diﬀerent combinations
of S1PR1–3 double null mice and triple null mice. They
found that S1PR1 S1PR2 double null and S1PR1 S1PR2
S1PR3 triple null embryos displayed a substantially more
severe vascularphenotype than embryos lacking only S1PR1.
All these embryos completed vasculogenesis regularly but
displayed immature vessels in the brain indicating that the
S1PR1 and S1PR2 receptors are required for some aspects
of vessel development during angiogenesis. In addition, the
researchers found partial embryonic lethality and vascu-
lar abnormalities in S1PR2 S1PR3 double null embryos.
Ultrastructural analysis of microvessels in the S1PR2 S1PR3
double null mice showed abnormal endothelial cells with
thin cell bodies, suggesting that these vessels may be fragile
and prone to rupture [102]. However, despite no obvious
anatomical defects in either S1PR2 or S1PR3 null mice,
S1PR2nullmiceexhibitearlylifedeafnesswhichisassociated
with pathologic changes within the cochlea. Most likely this
phenotype is caused by vascular disturbance within the stria
vascularis. Additionally, it was reported, that S1PR2 knock-
out mice display a vascular dysfunction aﬀecting the renal,
mesenterical, and, furthermore, aortic hemodynamics [103].
S1PR2 S1PR3 double null mice display stronger defects even
leading to head tilt while S1PR3 null mice do not share this
phenotype [104]. These data further support the hypothesis
of overlapping S1P receptor function with both partial
redundancy and unique receptor properties. Apart from that
there is growing evidence that S1PR2 also participates in
pathological neovascularisation. Skoura et al. [105]f o u n d
that S1PR2 null mice display reduced neovascularisation
in response to ischemia-driven retinopathy. Furthermore,
the inﬂammatory reaction that is usually concomitant to
ischemic retinopathy was suppressed in mice lacking S1PR2.
Therefore S1PR2 antagonism could be a potential target for
treatment of pathologic neovascularisation [105].
3.2.5. S1P and the Recruitment of Stem/Progenitor Cells.
Homing is the ﬁrst process in which circulating hematopoi-
etic cells actively cross the blood-bone-marrow-endothelium
barrier and stay at least temporarily in the bone marrow
compartment to undergo self-renewal. There is overwhelm-
ing evidence that circulating progenitor cells are responsible
for vascular healing and remodelling under physiological
and pathological conditions [106]. Usually stem/progenitor
cells persist in a quiescent state in their niche. In case of
angiogenesis or neovascularisation speciﬁc signals initiate
diﬀerentiation, furthermobilization, andhomingofvascular
progenitor cells [107]. Seitz et al. could already show8 Stem Cells International
that S1P is acting on hematopoietic progenitor cells as
chemoattractant via S1PR1. Given the fact that activated
platelets represent a major source of extracellular S1P, stem
cell homing may occur at sites of tissue injury in addition to
the bone marrow [108]. Walter et al. found that incubation
of patient-derived endothelial progenitor cells (EPCs) with
S1P or its synthetic analogue FTY720 improved blood ﬂow
recovery in ischemic hind limbs. This phenomenon was
critically dependent on S1PR3 activity since it was abolished
in S1P3 null mice [109]. In a recent study from Donati and
colleagues, S1P was found to be essential for mesoangioblast
proliferation and survival [110]. In summarize, S1P is
likely to act on diﬀerent immature cell types regarding the
mesendodermal germ layer.
3.3. Lysophosphatidic Acid. Similar to the other bioactive
lipids LPA seems to be involved in modulation of car-
diomyocyte signalling. Recently, elevated serum LPA con-
centrations in patients with myocardial infarction have been
reported, indicating a role of LPA in cardiac pathophysiology
[111]. In cultured neonatal cardiomyocytes, LPA induces
via LPA1/LPA3 hypertrophy under involvement of AKT
and NFκB signalling [112, 113]. Furthermore, it prevents
hypoxia-induced apoptosis in cardiomyocytes similar to
S1P and SPC [82]. Hence, LPA is likely to play a role
in left ventricular remodelling. Nevertheless, diﬀerentiation
inducing eﬀects of LPA in terms of cardiac development
remain to be established. So far, a developmental role of
LPA is restricted to the nervous system where LPA plays an
elementary function during neurogenesis.
3.3.1. LPA Functions Similarly But Not Equally as S1P during
Vasculogenesis. Regarding vessel formation LPA seems to
induce similar but not equal eﬀects compared to S1P. For
example, LPA has been shown to induce expression of MMPs
and migration of endothelial cells, both steps known to be
critical for vessel formation [114, 115]. However, LPA aﬀects
MMP induction and migration to a much lower extent than
S1P though it most likely uses the same signalling pathways.
Given the fact that LPA is a low-aﬃnity ligand of, for
example,theS1Preceptor[116],itcouldbepossiblethatLPA
eﬀects on endothelial cells are driven by S1P receptors [100,
114, 115, 117]. In mesenchymal stem cells LPA fails to induce
tube formation but promotes vascular network formation
in murine E8.5 allantois explants, still, in both studies less
eﬃcaciously than S1P [100, 118]. Despite controversial in
vitro data, in vivo studies of receptor or enzyme knockouts
aﬀecting LPA signalling showed gross abnormalities includ-
ing in angiogenesis. Homozygous LPAR1 null mice showed
50% neonatal lethality and reduced size caused by impaired
suckling behaviour. Beside the neuronal phenotype LPAR1
null mice also suﬀered from craniofacial dysmorphism,
uniformly notable by short snouts and widely spaced eyes.
This phenotype is most likely due to loss of LPAR1 during
developmentoffacialbonetissue,whereexpressionisusually
strong [119]. In addition, a small group of the knock out
animalsdisplayedfrontalhematoma.Thiscouldbeexplained
byimpropervasculogenesis,similartothephenotypeofS1P-
receptor knock out studies showing abnormal limb/bone
development [90]. However, given the small number of
LPAR1 null pups developing frontal hematoma, functional
angiogenic redundancy is likely also true for LPA receptors.
This issue is underlined by data achieved from LPAR1
and LPAR2 double null animals showing a more severe
phenotype.ThereforeLPAR1andLPAR2arenotessentialfor
proper development but most likely involved in mediation
of LPA-induced angiogenic signals [120]. In contrast, a
recent study identiﬁed LPAR4 as a critical regulator of the
structure and function of blood and lymphatic vessels [121].
T h eo v e r a l ln o ts e v e r ep h e n o t y p eo fa l ls i n g l eL P Ar e c e p t o r
null animals stands in striking contrast with autotaxin null
animals [122]. Lack of autotaxin leads to embryonic lethality
around E9.5 with profound vascular defects in yolk sac and
the embryos resemble the phenotype of animals lacking both
smallG-proteinG12 andG13.ThesetwoG-proteinsaremajor
mediators of LPA receptor signalling [123]. Furthermore,
ATX-deﬁcientembryosshowedallantoismalformation,neu-
ral tube defects, and asymmetric headfolds [122]. However,
developmental dysfunction is not only due to lack of LPA but
also to excess shown by knock out studies of lipid phosphate
phosphatases (LPPs), a group of enzymes involved in lipid
phosphate biosynthesis. Escalante-Alcalde and colleagues
disrupted the LPP3 gene leading to increased LPA levels.
LPPR3 null mice failed to form a chorioallantoic placenta
and yolk sac vasculature. Furthermore, some embryos exhib-
ited shortening of the anterior-posterior axis and frequent
duplication of axial structures [124]. To summarize this
section, LPA and its distinct receptors are most likely,
similar to the S1P-S1P receptor axis, functionally redundant
and therefore only triple or quadruple knock outs would
resemble the phenotype of ATX null animals and mirror, as
major LPA synthesizer, an LPA-deﬁcient phenotype. Hence,
it seems crystal clear that developmental importance of LPA
is not restricted to the neuronal systems but rather widely
aﬀects mammalian development.
4. Conclusion
There are several lines of evidence pointing to lysophospho-
lipids or bioactive lipids as important regulators of stem
cell diﬀerentiation in vitro and cardiovascular development
in vivo. This has been established by a variety of studies
using either knock out mouse models or embryonic stem
cells as tools to recapitulate cardiovascular development. In
particular S1P seems to be crucial for this particular system
while LPA seems to be more pronounced in the nervous
system. However, the SPC role in this process seems to be
underdeveloped so far and needs further studies to dissect its
developmental impact more precisely.
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